Jean‐Pascal Machiels

6.8k total citations
58 papers, 1.6k citations indexed

About

Jean‐Pascal Machiels is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean‐Pascal Machiels has authored 58 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Jean‐Pascal Machiels's work include Head and Neck Cancer Studies (17 papers), Lung Cancer Treatments and Mutations (6 papers) and Peptidase Inhibition and Analysis (5 papers). Jean‐Pascal Machiels is often cited by papers focused on Head and Neck Cancer Studies (17 papers), Lung Cancer Treatments and Mutations (6 papers) and Peptidase Inhibition and Analysis (5 papers). Jean‐Pascal Machiels collaborates with scholars based in Belgium, France and Italy. Jean‐Pascal Machiels's co-authors include Sandra Schmitz, Marc Hamoir, Emmanuel Seront, Vincent Grégoire, Leisha A. Emens, François‐Xavier Hanin, Elizabeth M. Jaffee, R. Todd Reilly, Thierry Duprez and Yves Humblet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jean‐Pascal Machiels

55 papers receiving 1.5k citations

Peers

Jean‐Pascal Machiels
Anthony Kong United Kingdom
Eirini Pectasides Greece
Jenny Huang United States
Sang‐Hue Yen Taiwan
Dora Lai‐Wan Kwong Hong Kong
Marc Oliva Spain
Stefan Kasper Germany
Moritz Jesinghaus Germany
Ammar Sukari United States
Seija Grénman Finland
Anthony Kong United Kingdom
Jean‐Pascal Machiels
Citations per year, relative to Jean‐Pascal Machiels Jean‐Pascal Machiels (= 1×) peers Anthony Kong

Countries citing papers authored by Jean‐Pascal Machiels

Since Specialization
Citations

This map shows the geographic impact of Jean‐Pascal Machiels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Pascal Machiels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Pascal Machiels more than expected).

Fields of papers citing papers by Jean‐Pascal Machiels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Pascal Machiels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Pascal Machiels. The network helps show where Jean‐Pascal Machiels may publish in the future.

Co-authorship network of co-authors of Jean‐Pascal Machiels

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Pascal Machiels. A scholar is included among the top collaborators of Jean‐Pascal Machiels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Pascal Machiels. Jean‐Pascal Machiels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mehra, Niven, Karim Fizazi, Johann S. de Bono, et al.. (2022). Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. The Oncologist. 27(10). e783–e795. 11 indexed citations
2.
Bouaoud, Jebrane, Paolo Bossi, Moshe Elkabets, et al.. (2022). Unmet Needs and Perspectives in Oral Cancer Prevention. Cancers. 14(7). 1815–1815. 24 indexed citations
3.
Verbiest, Annelies, Diether Lambrechts, Thomas Van Brussel, et al.. (2018). Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer. 16(4). 266–273. 8 indexed citations
4.
Balincourt, Christine de, Denis Lacombe, Corneel Coens, et al.. (2017). Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC). European Journal of Cancer. 86. 91–100. 13 indexed citations
5.
Filleul, Bertrand, et al.. (2016). Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment. Urologia Internationalis. 100(3). 357–360. 8 indexed citations
6.
Schmitz, Sandra, François P. Duhoux, & Jean‐Pascal Machiels. (2015). Window of opportunity studies: Do they fulfil our expectations?. Cancer Treatment Reviews. 43. 50–57. 29 indexed citations
7.
Berlière, Martine, François P. Duhoux, Florence Dalenc, et al.. (2013). Correction: Tamoxifen and Ovarian Function. PLoS ONE. 8(10). 10 indexed citations
8.
Machiels, Jean‐Pascal & Sandra Schmitz. (2011). Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy. Current Opinion in Oncology. 23(3). 241–248. 17 indexed citations
9.
Machiels, Jean‐Pascal & Sandra Schmitz. (2011). Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy. 11(3). 359–371. 5 indexed citations
10.
Grégoire, Vincent, Marc Hamoir, Changhu Chen, et al.. (2011). Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and Oncology. 100(1). 62–69. 35 indexed citations
11.
Hamoir, Marc, Alfio Ferlito, Sandra Schmitz, et al.. (2011). The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncology. 48(3). 203–210. 59 indexed citations
12.
Machiels, Jean‐Pascal & Sandra Schmitz. (2010). New advances in targeted therapies for squamous cell carcinoma of the head and neck. Anti-Cancer Drugs. 22(7). 626–633. 9 indexed citations
13.
Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120. Cancer Research. 69(2). 1 indexed citations
14.
Forget, Patrice, et al.. (2009). Does intraoperative analgesia influence cancer relapse after mastectomy? A retrospective analysis. European Journal of Anaesthesiology. 26. 186–187. 1 indexed citations
15.
Machiels, Jean‐Pascal. (2009). Combining Docetaxel With Estramustine: Back to the Future? REPLY. Journal of Clinical Oncology. 27(7). 1149–1150.
16.
Seront, Emmanuel & Jean‐Pascal Machiels. (2009). Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma. Recent Patents on Anti-Cancer Drug Discovery. 4(2). 146–156. 6 indexed citations
17.
Schmitz, Sandra, Jean‐Pascal Machiels, Birgit Weynand, Vincent Grégoire, & Marc Hamoir. (2008). Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 266(3). 437–443. 44 indexed citations
18.
Robert, Annie, et al.. (2007). Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. European Archives of Oto-Rhino-Laryngology. 264(6). 587–594. 27 indexed citations
19.
Machiels, Jean‐Pascal, Véronique D’Hondt, Anne-Sophie Govaerts, et al.. (1998). Retroviral-mediated gene transfer of human multidrug resistance associated murine hematopoietic cells. British Journal of Haematology. 102(1). 18. 1 indexed citations
20.
D’Hondt, Véronique, Jean‐Pascal Machiels, Manuel Caruso, Alexander Bank, & Michel Symann. (1997). Chemoresistance in hematopoietic cells by retroviral gene transfer of the multidrug resistance-associated protein (MRP) cDNA.. Experimental Hematology. 25(8). 8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony Kong Breakdown of academic impact, for papers by Eirini Pectasides Breakdown of academic impact, for papers by Jenny Huang Breakdown of academic impact, for papers by Sang‐Hue Yen Breakdown of academic impact, for papers by Dora Lai‐Wan Kwong Breakdown of academic impact, for papers by Marc Oliva Breakdown of academic impact, for papers by Stefan Kasper Breakdown of academic impact, for papers by Moritz Jesinghaus Breakdown of academic impact, for papers by Ammar Sukari Breakdown of academic impact, for papers by Seija Grénman
Rankless by CCL
2026